Van Morris, MD
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Van Morris, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:56 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07511023 · Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/RectumM.D. Anderson Cancer Center · not yet recruiting · Phase 2, Sacituzumab Tirumotecan, Refractory Metastatic · principal investigator
- Ph1/Ph2NCT07137390 · A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal CancerM.D. Anderson Cancer Center · withdrawn · Colorectal Cancer · principal investigator
- Ph2NCT06617858 · Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent TreatmentM.D. Anderson Cancer Center · recruiting · Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 5 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.